Shanghai Pharmaceuticals Holding Co., Ltd (SHA:601607)
China · Delayed Price · Currency is CNY 17.25
+0.23 (1.35%)
Apr 15, 2026, 3:00 PM CST
SHA:601607 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 282,552 | 274,187 | 259,152 | 231,240 | 215,824 |
Other Revenue | 1,027 | 1,064 | 1,143 | 741.24 | - |
| 283,580 | 275,251 | 260,295 | 231,981 | 215,824 | |
Revenue Growth (YoY) | 3.03% | 5.75% | 12.21% | 7.49% | 12.46% |
Cost of Revenue | 253,207 | 244,837 | 229,366 | 201,604 | 187,416 |
Gross Profit | 30,373 | 30,413 | 30,929 | 30,377 | 28,408 |
Selling, General & Admin | 18,458 | 18,326 | 19,527 | 19,173 | 18,376 |
Research & Development | 2,340 | 2,394 | 2,204 | 2,112 | 1,987 |
Other Operating Expenses | 640.28 | 143.51 | 376.86 | 654.72 | 633.18 |
Operating Expenses | 21,910 | 21,096 | 22,349 | 22,214 | 20,942 |
Operating Income | 8,463 | 9,317 | 8,581 | 8,164 | 7,466 |
Interest Expense | -1,686 | -1,857 | -1,885 | -1,689 | -1,518 |
Interest & Investment Income | 3,575 | 902.81 | 461.83 | 971.41 | 2,150 |
Currency Exchange Gain (Loss) | -62.04 | -73.93 | 11.41 | 21.51 | 10.1 |
Other Non Operating Income (Expenses) | -168.04 | -166.21 | -109.59 | -116.44 | -128.71 |
EBT Excluding Unusual Items | 10,122 | 8,123 | 7,059 | 7,351 | 7,979 |
Impairment of Goodwill | -328.53 | -230.47 | - | - | -19.21 |
Gain (Loss) on Sale of Investments | 332.12 | 178.43 | 155.93 | 218.74 | -206 |
Gain (Loss) on Sale of Assets | 157.15 | 187.97 | 92.48 | 1,439 | 58.29 |
Asset Writedown | -707.97 | -218.05 | -70.65 | -322.79 | -69.77 |
Legal Settlements | -46.79 | -26.56 | -12.69 | -37.38 | -8.1 |
Other Unusual Items | 292.17 | 5.56 | -169.95 | 160.13 | 409.61 |
Pretax Income | 9,820 | 8,020 | 7,054 | 8,808 | 8,144 |
Income Tax Expense | 2,846 | 2,150 | 1,888 | 1,816 | 1,869 |
Earnings From Continuing Operations | 6,974 | 5,870 | 5,167 | 6,992 | 6,275 |
Minority Interest in Earnings | -1,249 | -1,317 | -1,399 | -1,375 | -1,181 |
Net Income | 5,725 | 4,553 | 3,768 | 5,617 | 5,093 |
Net Income to Common | 5,725 | 4,553 | 3,768 | 5,617 | 5,093 |
Net Income Growth | 25.75% | 20.82% | -32.92% | 10.28% | 13.28% |
Shares Outstanding (Basic) | 3,708 | 3,704 | 3,701 | 3,483 | 2,842 |
Shares Outstanding (Diluted) | 3,708 | 3,704 | 3,701 | 3,483 | 2,842 |
Shares Change (YoY) | 0.11% | 0.07% | 6.28% | 22.54% | - |
EPS (Basic) | 1.54 | 1.23 | 1.02 | 1.61 | 1.79 |
EPS (Diluted) | 1.54 | 1.23 | 1.02 | 1.61 | 1.79 |
EPS Growth | 25.30% | 20.73% | -36.77% | -10.06% | 13.29% |
Free Cash Flow | 3,828 | 3,426 | 2,261 | 2,058 | 942.55 |
Free Cash Flow Per Share | 1.03 | 0.93 | 0.61 | 0.59 | 0.33 |
Dividend Per Share | 0.470 | 0.370 | 0.410 | 0.610 | 0.420 |
Dividend Growth | 27.03% | -9.76% | -32.79% | 45.24% | -12.50% |
Gross Margin | 10.71% | 11.05% | 11.88% | 13.10% | 13.16% |
Operating Margin | 2.98% | 3.38% | 3.30% | 3.52% | 3.46% |
Profit Margin | 2.02% | 1.65% | 1.45% | 2.42% | 2.36% |
Free Cash Flow Margin | 1.35% | 1.24% | 0.87% | 0.89% | 0.44% |
EBITDA | 10,452 | 11,015 | 10,081 | 9,689 | 8,973 |
EBITDA Margin | 3.69% | 4.00% | 3.87% | 4.18% | 4.16% |
D&A For EBITDA | 1,990 | 1,698 | 1,500 | 1,526 | 1,507 |
EBIT | 8,463 | 9,317 | 8,581 | 8,164 | 7,466 |
EBIT Margin | 2.98% | 3.38% | 3.30% | 3.52% | 3.46% |
Effective Tax Rate | 28.98% | 26.81% | 26.76% | 20.62% | 22.95% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.